Cite
Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects.
MLA
Romito, Ilaria, et al. “Correction to: Focal Adhesion Kinase Inhibitor TAE226 Combined with Sorafenib Slows down Hepatocellular Carcinoma by Multiple Epigenetic Effects.” Journal of Experimental & Clinical Cancer Research (17569966), vol. 41, no. 1, Jan. 2022, pp. 1–6. EBSCOhost, https://doi.org/10.1186/s13046-022-02247-y.
APA
Romito, I., Porru, M., Braghini, M. R., Pompili, L., Panera, N., Crudele, A., Gnani, D., De Stefanis, C., Scarsella, M., Pomella, S., Mortera, S. L., de Billy, E., Conti, A. L., Marzano, V., Putignani, L., Vinciguerra, M., Balsano, C., Pastore, A., Rota, R., & Tartaglia, M. (2022). Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects. Journal of Experimental & Clinical Cancer Research (17569966), 41(1), 1–6. https://doi.org/10.1186/s13046-022-02247-y
Chicago
Romito, Ilaria, Manuela Porru, Maria Rita Braghini, Luca Pompili, Nadia Panera, Annalisa Crudele, Daniela Gnani, et al. 2022. “Correction to: Focal Adhesion Kinase Inhibitor TAE226 Combined with Sorafenib Slows down Hepatocellular Carcinoma by Multiple Epigenetic Effects.” Journal of Experimental & Clinical Cancer Research (17569966) 41 (1): 1–6. doi:10.1186/s13046-022-02247-y.